Apr. 21 at 3:41 PM
$KTTA $KTTA $KTTA trading near its’ 52-week low and look what’s on the table:
1) they had
$60 million raise through a public offering in December 2025
2) management has stated they have enough cash to fund operations through the first half of 2028
3) FDA granted the Rare Pediatric Disease Fesignation for their lead drug PAS-004 which qualifies them for fast track designation. Great news and the cherry on top: Pasisthea is now eligible for a Priority Review Voucher if the drug gets approved. These vouchers are valuable and can be sold for
$150-
$200 million dollars. That would offer up a lot of non-dilutive funding for the company.
4)H.C. Wainwright & Co. reiterated a buy as of April 20th, and assigned a price target of
$3.00.
So what’s not to like about that! Time to get your cheap shares because, in my opinion, this is going to pop at some point soon!
